1. Netherlands Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Qiagen N.V.

Qiagen N.V.

QGEN
Qiagen N.V.US flagNew York Stock Exchange
35.69
USD
-0.49
- -
7.35BMarket Cap
Qiagen N.V.
QGEN
(New York Stock Exchange)

Recent

price

35.69

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.41
5.79
6.2
6.45
6.72
6.37
6.61
6.94
7.43
7.48
9.14
11.07
10.19
9.61
9.64
10.13
10.18
Revenue per Share
0.72
0.48
0.64
0.34
0.58
0.65
0.4
0.2
0.94
-0.2
1.76
2.52
2.01
1.67
0.41
2.06
1.95
Basic EPS, GAAP
0.63
0.61
0.58
0.7
0.95
1
1.22
0.79
1.03
0.27
0.75
2.13
2.69
1.45
2.45
2.17
1.96
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.26
- -
Dividend per Share
3.79
4.25
4.88
5.24
5.64
6.03
6.26
6.12
6.84
5.79
6.48
8.82
10.29
12.03
11.94
13.33
13.6
Book Value per Share
1.84
0.02
0.55
0.39
0.22
0.28
0.61
0.14
0.25
-1.16
-1.43
0.58
2.71
3.94
4.08
3.35
1.3
Tangible Book Value per Share
201
202
202
202
200
201
202
204
202
204
205
203
210
204
205
206
206
Basic Weighted Avg Shares
1,087
1,170
1,254
1,302
1,345
1,281
1,338
1,418
1,502
1,526
1,870
2,252
2,142
1,965
1,978
2,090
2,099
Sales/Revenue/Turnover
17.34
8.51
13.54
4.86
12.02
14.01
7.39
17.74
20.19
20.55
28.74
29.22
26.91
22.66
10.11
24.9
24.38
Operating Margin (%)
143
167
198
199
201
191
213
216
206
231
205
215
208
205
203
194
201
Depreciation Expense
144
96
130
69
116
130
80
40
190
-41
359
513
423
341
84
425
402
Net Income, GAAP
16.64
1.31
10.76
- -
2.06
4.7
- -
64.68
15.66
- -
18.27
18.09
17.44
20.59
31
13.34
11.91
Effective Tax Rate (%)
13.27
8.21
10.32
5.31
8.65
10.16
6.01
2.85
12.68
-2.72
19.2
22.77
19.76
17.37
4.23
20.33
19.16
Profit Margin (%)
976
294
726
584
717
693
729
1,323
1,183
619
1,052
592
1,419
1,068
918
1,483
1,061
Working Capital
797
446
846
845
1,041
1,049
1,067
1,758
1,671
1,421
1,880
1,094
1,472
922
936
1,784
1,647
LT Debt
2,476
2,558
2,724
2,724
2,658
2,568
2,607
2,541
2,635
2,537
2,798
3,097
3,467
3,808
3,567
3,778
3,332
Total Equity
4.73
2.98
4.48
- -
4.25
4.57
- -
2.22
5.59
- -
9.75
11
9.14
6.62
2.65
8.43
9.24
Return on Invested Capital (%)
10.55
7.89
9.08
- -
7.3
7.26
- -
2.17
7.53
- -
13.51
15.85
12.08
9.55
2.86
10.64
10.4
Return on Capital (%)
20.9
11.85
14.02
6.75
10.65
11.12
6.49
3.21
14.46
-3.23
28.66
32.86
21.39
14.77
3.4
16.34
15.16
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
500
29
- -
LT Borrowings
1,628
1,654
1,647
LT Finance Leases
- -
129
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
206
206
206
Market Capitalization
9,333
9,898
8,258

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
2,531
1,995
1,540
Cash, Cash Equivalents & STI
1,690
1,099
646
Accounts Receivable, Net
376
403
397
Inventories
290
302
310
Total Current Liabilities
973
512
479
Payables & Accruals
474
310
479
ST Debt
500
29
- -
Deferred Revenue
- -
79
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.13%
6.41%
5.91%
Free Cash Flow
34.24%
44.65%
-10.97%
Net Income, GAAP
-46.62%
67.74%
408.28%
Sales/Revenue/Turnover
5.41%
2.72%
5.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
459
496
502
521
1,978
2025
483
534
533
540
2,090
2026
492
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.38
-0.87
0.46
0.43
0.41
2025
0.42
0.47
0.63
0.52
2.06
2026
0.33
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.26
2026
- -
- -
- -
- -
- -
Similar Companies
Diagnósticos da América S.A. (DASA3.SA)
Thermo Fisher Scientific Inc. (0R0H.L)
BGI Genomics Co., Ltd. (300676.SZ)
Eurofins Scientific SE (ERF.PA)
BioNexus Gene Lab Corp. (BGLC)
Predilife S.A. (ALPRE.PA)
Business
QIAGEN N.V. (NYSE: QGEN; Frankfurt: QIA) provides Sample to Insight solutions that enable molecular diagnostics, applied testing, academic and pharmaceutical research, and bioinformatics through products and services for extracting, analyzing and interpreting insights from DNA, RNA and proteins. The company offers sample technologies including kits, consumables and automated instruments for nucleic acid isolation and processing from blood, tissue and other materials; assay technologies such as PCR, next-generation sequencing (NGS) panels like QIAseq xHYB Long Read Panels for structural variants, HLA typing and repeat expansions, multiplex real-time PCR systems like QIAstat-Dx, and immunoassay platforms like QuantiFERON for latent TB detection; bioinformatics software and knowledge bases for data interpretation; and automation solutions including QIAmini, QIAsprint Connect and QIAsymphony Connect for high-throughput workflows. Founded in 1984 and headquartered in Venlo, Netherlands, with main operational headquarters in Hilden, Germany, and regional offices in the United States, China and Singapore, QIAGEN serves over 500,000 customers worldwide including academia, pharma/biotech R&D, clinical labs, forensics, veterinary and food safety sectors across more than 35 countries. In recent developments, QIAGEN acquired Parse Biosciences in November 2025 for $225 million upfront plus up to $55 million in milestones to enter the single-cell sequencing market supporting AI-driven biology; announced a $500 million synthetic share repurchase to complete in early January 2026 as part of over $1 billion in shareholder returns since 2024; launched QIAseq xHYB Long Read Panels in 2025 to enhance NGS target enrichment; exceeded Q3 2025 financial outlook with raised full-year adjusted EPS guidance; and advanced launches of three new sample preparation instruments in 2025-2026 targeting liquid biopsy, oncology and high-throughput applications.

Company News

APIChat

  • zacks.com

    Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?

  • businesswire.com

    QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

  • zacks.com

    QIAGEN Business Breakdown and Growth Drivers for 2026

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

  • globenewswire.com

    QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.

  • globenewswire.com

    QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

  • zacks.com

    QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform

  • businesswire.com

    QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

  • zacks.com

    3 Stocks in Focus That Recently Declared Dividend Hikes Amid High Inflation

  • prnewswire.com

    Qiagen (QGEN) Securities Fraud Investigation - Levi & Korsinsky

  • businesswire.com

    QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

  • businesswire.com

    QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

  • globenewswire.com

    QIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V. on Behalf of Qiagen Stockholders and Encourages Investors to Contact the Firm

  • globenewswire.com

    QIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V.

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

  • globenewswire.com

    QGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

  • globenewswire.com

    Levi & Korsinsky Announces Investigation of Securities Claims Against Qiagen N.V. (QGEN)